Cargando…

Longitudinal observation of serum anti-Müllerian hormone in three girls after cancer treatment

Gonadal dysfunction and infertility are major endocrinological late effects among childhood cancer survivors. Chemotherapy and radiation have gonadotoxic effects and diminish the ovarian reserve. The serum concentration of anti-Müllerian hormone (AMH) is a useful marker of ovarian reserve in survivo...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyoshi, Yoko, Yasuda, Kie, Tachibana, Makiko, Yoshida, Hisao, Miyashita, Emiko, Miyamura, Takako, Hashii, Yoshiko, Hashimoto, Kae, Kimura, Tadashi, Ozono, Keiichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society for Pediatric Endocrinology 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069540/
https://www.ncbi.nlm.nih.gov/pubmed/27780981
http://dx.doi.org/10.1297/cpe.25.119
_version_ 1782460954809729024
author Miyoshi, Yoko
Yasuda, Kie
Tachibana, Makiko
Yoshida, Hisao
Miyashita, Emiko
Miyamura, Takako
Hashii, Yoshiko
Hashimoto, Kae
Kimura, Tadashi
Ozono, Keiichi
author_facet Miyoshi, Yoko
Yasuda, Kie
Tachibana, Makiko
Yoshida, Hisao
Miyashita, Emiko
Miyamura, Takako
Hashii, Yoshiko
Hashimoto, Kae
Kimura, Tadashi
Ozono, Keiichi
author_sort Miyoshi, Yoko
collection PubMed
description Gonadal dysfunction and infertility are major endocrinological late effects among childhood cancer survivors. Chemotherapy and radiation have gonadotoxic effects and diminish the ovarian reserve. The serum concentration of anti-Müllerian hormone (AMH) is a useful marker of ovarian reserve in survivors. We conducted a longitudinal study to investigate the variations of AMH in evaluating the acute and chronic effects of cancer therapy on the ovary. Three young female patients with different hematological diseases were registered, and their medical records were reviewed. Patient 1 with myelodysplastic syndrome received reduced-intensity hematopoietic stem cell transplantation (HSCT) at 10 yr of age. Breast development and menarche occurred spontaneously after HSCT; however, AMH level became undetectable and gonadotropin did not increase. Patient 2 with acute lymphoblastic leukemia had been receiving chemotherapy since 11 yr of age. AMH level became undetectable but increased after chemotherapy and was associated with regular menstruation. Patient 3 with acute myeloid leukemia received chemotherapy at 13 yr of age and myeloablative HSCT at 14 yr of age. AMH level became undetectable after HSCT, and the patient developed amenorrhea. These different patterns in the recovery phase demonstrated that the AMH level immediately after the end of cancer therapy is inappropriate for the evaluation of the ovarian reserve.
format Online
Article
Text
id pubmed-5069540
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher The Japanese Society for Pediatric Endocrinology
record_format MEDLINE/PubMed
spelling pubmed-50695402016-10-25 Longitudinal observation of serum anti-Müllerian hormone in three girls after cancer treatment Miyoshi, Yoko Yasuda, Kie Tachibana, Makiko Yoshida, Hisao Miyashita, Emiko Miyamura, Takako Hashii, Yoshiko Hashimoto, Kae Kimura, Tadashi Ozono, Keiichi Clin Pediatr Endocrinol Original Article Gonadal dysfunction and infertility are major endocrinological late effects among childhood cancer survivors. Chemotherapy and radiation have gonadotoxic effects and diminish the ovarian reserve. The serum concentration of anti-Müllerian hormone (AMH) is a useful marker of ovarian reserve in survivors. We conducted a longitudinal study to investigate the variations of AMH in evaluating the acute and chronic effects of cancer therapy on the ovary. Three young female patients with different hematological diseases were registered, and their medical records were reviewed. Patient 1 with myelodysplastic syndrome received reduced-intensity hematopoietic stem cell transplantation (HSCT) at 10 yr of age. Breast development and menarche occurred spontaneously after HSCT; however, AMH level became undetectable and gonadotropin did not increase. Patient 2 with acute lymphoblastic leukemia had been receiving chemotherapy since 11 yr of age. AMH level became undetectable but increased after chemotherapy and was associated with regular menstruation. Patient 3 with acute myeloid leukemia received chemotherapy at 13 yr of age and myeloablative HSCT at 14 yr of age. AMH level became undetectable after HSCT, and the patient developed amenorrhea. These different patterns in the recovery phase demonstrated that the AMH level immediately after the end of cancer therapy is inappropriate for the evaluation of the ovarian reserve. The Japanese Society for Pediatric Endocrinology 2016-10-18 2016-10 /pmc/articles/PMC5069540/ /pubmed/27780981 http://dx.doi.org/10.1297/cpe.25.119 Text en 2016©The Japanese Society for Pediatric Endocrinology http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License.
spellingShingle Original Article
Miyoshi, Yoko
Yasuda, Kie
Tachibana, Makiko
Yoshida, Hisao
Miyashita, Emiko
Miyamura, Takako
Hashii, Yoshiko
Hashimoto, Kae
Kimura, Tadashi
Ozono, Keiichi
Longitudinal observation of serum anti-Müllerian hormone in three girls after cancer treatment
title Longitudinal observation of serum anti-Müllerian hormone in three girls after cancer treatment
title_full Longitudinal observation of serum anti-Müllerian hormone in three girls after cancer treatment
title_fullStr Longitudinal observation of serum anti-Müllerian hormone in three girls after cancer treatment
title_full_unstemmed Longitudinal observation of serum anti-Müllerian hormone in three girls after cancer treatment
title_short Longitudinal observation of serum anti-Müllerian hormone in three girls after cancer treatment
title_sort longitudinal observation of serum anti-müllerian hormone in three girls after cancer treatment
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069540/
https://www.ncbi.nlm.nih.gov/pubmed/27780981
http://dx.doi.org/10.1297/cpe.25.119
work_keys_str_mv AT miyoshiyoko longitudinalobservationofserumantimullerianhormoneinthreegirlsaftercancertreatment
AT yasudakie longitudinalobservationofserumantimullerianhormoneinthreegirlsaftercancertreatment
AT tachibanamakiko longitudinalobservationofserumantimullerianhormoneinthreegirlsaftercancertreatment
AT yoshidahisao longitudinalobservationofserumantimullerianhormoneinthreegirlsaftercancertreatment
AT miyashitaemiko longitudinalobservationofserumantimullerianhormoneinthreegirlsaftercancertreatment
AT miyamuratakako longitudinalobservationofserumantimullerianhormoneinthreegirlsaftercancertreatment
AT hashiiyoshiko longitudinalobservationofserumantimullerianhormoneinthreegirlsaftercancertreatment
AT hashimotokae longitudinalobservationofserumantimullerianhormoneinthreegirlsaftercancertreatment
AT kimuratadashi longitudinalobservationofserumantimullerianhormoneinthreegirlsaftercancertreatment
AT ozonokeiichi longitudinalobservationofserumantimullerianhormoneinthreegirlsaftercancertreatment